MT1G was previously reported to inhibit ferroptosis by blocking glutathione depletion-mediated lipid peroxidation in hepatocellular carcinoma cells and clear cell renal cell carcinoma, and to promote sorafenib resistance in hepatocellular carcinoma cells. Here, MT1G is linked to clear cell renal carcinoma.